Overview

Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

Status:
RECRUITING

Trial end date:
2026-05-30

Target enrollment:

Participant gender:

Summary

This is a Phase 1/1b, open-label, dose-escalation study to evaluate the safety and the efficacy of anti-CD19 chimeric antigen receptor (CAR) (TBI-2001) for relapsed or refractory CD19+ B-cell lymphoma Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL).

Phase:

PHASE1

Details

Lead Sponsor:

University Health Network, Toronto

Collaborator:

Takara Bio Inc.

Treatments:

Cyclophosphamide
fludarabine